XML 47 R31.htm IDEA: XBRL DOCUMENT v3.22.4
REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)
12 Months Ended
Dec. 31, 2022
REVENUE FROM CONTRACTS WITH CUSTOMERS  
Summary of product revenue provision and allowance

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance at December 31, 2019

$

129,901

$

27,648

$

14,020

Provision related to current period sales

326,280

10,900

75,554

Changes in estimate related to prior period sales

(539)

(403)

Credits/payments made

(322,867)

(14,769)

(70,116)

Balance at December 31, 2020

$

132,775

$

23,779

$

19,055

Provision related to current period sales

378,694

27,229

84,470

Changes in estimate related to prior period sales

1,121

8,763

4

Credits/payments made

(370,211)

(5,154)

(90,303)

Balance at December 31, 2021

$

142,379

$

54,617

$

13,226

Acquired from BDSI

38,074

18,187

7,575

Provision related to current period sales

497,250

38,250

132,547

Changes in estimate related to prior period sales

(619)

2,505

(592)

Credits/payments made

(520,147)

(40,005)

(130,698)

Balance at December 31, 2022

$

156,937

$

73,554

$

22,058

(1)Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Consolidated Balance Sheets.

Schedule of disaggregation of revenue

Years Ended December 31,

2022

2021

2020

Belbuca

$

126,461

$

$

Xtampza ER

138,804

    

103,708

    

127,984

Nucynta IR

112,058

102,222

116,318

Nucynta ER

72,418

70,938

65,714

Symproic

12,267

Other

1,925

Total product revenues, net

$

463,933

$

276,868

$

310,016